BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares were up 10.7% during mid-day trading on Friday following a better than expected earnings announcement. The company traded as high as $8.62 and last traded at $8.7490. Approximately 2,803,466 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 4,386,014 shares. The stock had previously closed at $7.90.

The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. The firm had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The company’s revenue was up 209.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) earnings per share.

Key Headlines Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat expectations — GAAP EPS $1.12 vs. consensus ~$0.07 and quarterly revenue well above estimates, showing a large YoY revenue increase; the conference call and slide deck underscore improved profitability. BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Strong full‑year commercial performance — ORLADEYO® net revenue for FY2025 reported at $601.8M (up ~38% y/y), providing clear top-line strength and supporting improved guidance/positioning. BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Astria acquisition strengthens HAE franchise and company guidance — management highlighted the deal as strategic for HAE growth, which supports medium‑term revenue runway. BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
• Positive Sentiment: Analyst sentiment remains constructive — consensus rating reported as “Moderate Buy,” which can support demand in the shares as coverage highlights the company’s improved fundamentals. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts
• Neutral Sentiment: Market commentary is weighing valuation after the recent rebound — some pieces debate whether the stock still offers value following the run-up, so investor focus may turn to forward guidance and execution. Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound
• Neutral Sentiment: Additional coverage and materials — earnings snapshot and the full earnings presentation are available for investors who want the details behind the beat and margin dynamics. BioCryst Pharmaceuticals, Inc. 2025 Q4 – Results – Earnings Call Presentation
• Neutral Sentiment: Short‑interest data appears inconsistent in recent reports (figures showing zero/NaN), so watch for clarified short-position reporting — meaningful shorting could add volatility but current public metrics are unclear.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BCRX. HC Wainwright boosted their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Citizens Jmp decreased their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.64.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 21,773 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the sale, the insider directly owned 398,751 shares of the company’s stock, valued at approximately $3,050,445.15. The trade was a 5.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 183,453 shares of company stock worth $1,330,965. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in BCRX. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of BioCryst Pharmaceuticals by 7.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 1,288 shares in the last quarter. Royal Bank of Canada boosted its stake in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after buying an additional 1,458 shares in the last quarter. Cetera Investment Advisers grew its position in BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,494 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares in the last quarter. Finally, Main Management ETF Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock worth $1,005,000 after acquiring an additional 1,824 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 9.8%

The stock’s fifty day moving average price is $7.11 and its two-hundred day moving average price is $7.40. The stock has a market capitalization of $1.83 billion, a P/E ratio of -173.70 and a beta of 0.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.